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Abstract
We have recently identified conventional B2 cells as atherogenic and B1a cells as atheroprotective in hypercholesterolemic
ApoE
2/2 mice. Here, we examined the development of atherosclerosis in BAFF-R deficient ApoE
2/2 mice because B2 cells
but not B1a cells are selectively depleted in BAFF-R deficient mice. We fed BAFF-R
2/2 ApoE
2/2 (BaffR.ApoE DKO) and BAFF-
R
+/+ApoE
2/2 (ApoE KO) mice a high fat diet (HFD) for 8-weeks. B2 cells were significantly reduced by 82%, 81%, 94%, 72% in
blood, peritoneal fluid, spleen and peripheral lymph nodes respectively; while B1a cells and non-B lymphocytes were
unaffected. Aortic atherosclerotic lesions assessed by oil red-O stained-lipid accumulation and CD68+ macrophage
accumulation were decreased by 44% and 50% respectively. B cells were absent in atherosclerotic lesions of BaffR.ApoE DKO
mice as were IgG1 and IgG2a immunoglobulins produced by B2 cells, despite low but measurable numbers of B2 cells and
IgG1 and IgG2a immunoglobulin concentrations in plasma. Plasma IgM and IgM deposits in atherosclerotic lesions were also
reduced. BAFF-R deficiency in ApoE
2/2 mice was also associated with a reduced expression of VCAM-1 and fewer
macrophages, dendritic cells, CD4+ and CD8+ T cell infiltrates and PCNA+ cells in lesions. The expression of proinflammatory
cytokines, TNF-a, IL1-b and proinflammatory chemokine MCP-1 was also reduced. Body weight and plasma cholesterols
were unaffected in BaffR.ApoE DKO mice. Our data indicate that B2 cells are important contributors to the development of
atherosclerosis and that targeting the BAFF-R to specifically reduce atherogenic B2 cell numbers while preserving
atheroprotective B1a cell numbers may be a potential therapeutic strategy to reduce atherosclerosis by potently reducing
arterial inflammation.
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Introduction
Atherosclerosis is a chronic inflammatory disease of large
arteries initiated by lipid entry. Despite the therapeutic application
of lipid-lowering statins; atherosclerosis-related vascular disease
remains the major cause of mortality from heart attacks and
strokes. New therapies to attenuate the chronic inflammation in
atherosclerosis are therefore urgently sought that can be combined
with current lipid-control medications and healthy life-style
adaptation [1,2]. B cells together with other immune cells are
implicated in the pathogenesis and progression of atherosclerosis.
Previous studies have suggested that these B cells are atheropro-
tective [3,4]. However, in a major paradigm shift, we and Ait-
Oufella et al have reported that these B cells can be pathogenic
because their depletion by anti-CD20 monoclonal antibody
ameliorated atherosclerosis in ApoE
2/2 and LDLR
2/2 mice
[5,6]. In adoptive transfer experiments we have identified
conventional B2 B cells as an atherogenic B cell subset and
peritoneal B1a B cells as an atheroprotective B cell subset in
atherosclerosis [5,7]. Consequentially, we have proposed a
potential therapeutic strategy for atherosclerosis based on selective
depletion of atherogenic B2 B cells without depleting atheropro-
tective peritoneal B1a B cells [8].
B-cell activating factor (BAFF), also known as BlyS, TALL-1,
zTNF4 and THANK, is a member of the TNF superfamily
(TNFSF13B) that is produced by myeloid cells, non-lymphoid cells
and epithelial cells [9]. BAFF is required for maturation and
survival of B2 cells [10]. Its biological activities are mediated by
three receptors, BAFF-receptor (BAFF-R; TNFRSF13C), trans-
membrane activator-calcium modulator and cyclophilin ligand
interactor (TACI; TNFRSF13B) and B-cell maturation antigen
(BCMA; TNFRSF17) [11]. While TACI and BCMA can also
interact with the BAFF homologue, a proliferation-inducing ligand
(APRIL; TNFSF13), BAFF-R is expressed by all mature B cells
PLoS ONE | www.plosone.org 1 January 2012 | Volume 7 | Issue 1 | e29371and only binds BAFF to initiate signaling that is crucial for B cell
development and survival [12].
Mice with genetically disrupted BAFF-R gene and spontaneous
mutation in the BAFF-R gene show a significant reduction in
mature B2 cells without affecting B1a B cells [13,14]. Therefore
BAFF-R has properties that are suitable for therapeutic targeting
in atherosclerosis. Here, we have examined the role of BAFF-R in
atherosclerosis using ApoE
2/2 mice deficient in BAFF-R. We
report that atherosclerosis and arterial inflammation is markedly
reduced in hypercholesterolemic BAFF-R deficient ApoE
2/2
mice.
Results
Generation and characteristics of BAFF-R-deficient
ApoE
2/2 mouse
We generated BAFF-R
2/2 ApoE
2/2 (BaffR.ApoE DKO) mice
by crossing C57Bl/6 BAFF-R
2/2 mice with atherosclerosis-prone
C57Bl/6 ApoE
2/2 (ApoE KO) mice. Genotypes of BaffR.ApoE
DKO and ApoE KO mice were verified by PCR (Figure 1 A).
BaffR.ApoE DKO and ApoE KO mice were fed a high fat diet
(HFD) containing 21% fat and 0.15% cholesterol (Specialty Feed,
Western Australia) for eight weeks to study the role of BAFF-R in
atherosclerosis.
Genes encoding BAFF-R disrupted by spontaneous mutation
[13] or gene-targeted depletion [14] showed a decrease in mature
B cells. To confirm similar effects in the BaffR.ApoE DKO mice,
CD22+ B cell population was analyzed in different tissues at the
end of 8-week HFD period. We found that B cells were
significantly reduced in peripheral blood, peritoneal cavity, spleen
and lymph node by 82% (p,0.01), 81% (p,0.001), 94%
(p,0.001) and 72% (p,0.01) respectively in BAFF-R-deficient
ApoE
2/2 mice (Figure 1 B).
Although BAFF-R is necessary for maturation of B cells from
transitional B cells to follicular B cells and Marginal Zone B cells,
BAFF-R deletion has either no or minimal effects on the B1 B cell
linage [13,14]. In accordance with the literature, peritoneal
CD22+ CD5+ B1a cell population was not affected by depletion of
BAFF-R gene in ApoE
2/2 mice (p.0.05; Figure 1 C and D).
FACS analysis of splenic cells showed that non-B cell populations,
including CD4+CD25+ Foxp3 regulatory T cells were unaffected
in BAFF-R-deficient ApoE
2/2 mice (p.0.05; Table 1), consistent
with a previous report [14].
Hypercholesterolemia is an initiating factor in the pathogenesis
of atherosclerosis. Plasma lipid analysis showed that there was no
difference in plasma total cholesterol, HDL-cholesterol, VLDL/
LDL-cholesterol and triglycerides between BAFF-R-deficient and
–competent ApoE
2/2 mice fed a HFD for eight weeks (p.0.05;
Table 2). Similarly, BAFF-R depletion did not affect the body
weight in ApoE
2/2 mice (p.0.05; Table 2).
BaffR.ApoE DKO mice exhibit reduced atherosclerosis
Next, we asked if the deficiency in BAFF-R influences the
development of atherosclerosis in hypercholesterolemic
ApoE
2/2 mice. Assessment of atherosclerotic lesions after
feeding mice a HFD by oil red-O stained lipid accumulation
showed that BaffR.ApoE DKO mice had a significant ,44%
reduction in aortic atherosclerosis compared to ApoE KO mice
(p,0.01; Figure 2 A). We found that a similar ,50%
reduction in atherosclerosis as assessed by CD68-stained
macrophage accumulation in BaffR.ApoE DKO mice (p,0.05;
Figure 2 B).
Lack of B cells and immunoglobulins G in atherosclerotic
lesions of BaffR.ApoE DKO mice
We next determined whether B cell numbers were reduced in
lesions of BaffR.ApoE DKO mice using anti-CD22 immunohis-
tochemistry. In marked contrast to ApoE KO mice, there was no
accumulation of B cells in atherosclerotic lesions in BaffR.ApoE
DKO mice (p,0.001; Figure 3 A). As IgG1 and IgG2a are
produced by B2 cells, we also assessed their accumulation in
lesions. Again, in contrast to lesions of ApoE KO mice, those of
BaffR.ApoE DKO mice did not contain detectable quantities of
these two immunoglobulins (p,0.001 and p,0.05 respectively;
Figure 3 B and C), confirming the marked differences in B cell
accumulation between ApoE KO and BaffR.ApoE DKO mice. To
ensure that the reductions in lesion IgG1 and IgG2a were the
consequence of markedly different B cell numbers in lesions of
the two groups of mice, we also assessed circulating levels of
IgG1 and IgG2a. As expected, ELISA results revealed that the
plasma levels of IgG1 and IgG2a were decreased by 65% and
82% as the result of BAFF-R gene disruption (both p,0.01;
Figure 3 E).
BAFF-R deficiency reduced plasma IgM and IgM deposits
in lesions
ELISA results revealed that levels of plasma IgM in BaffR.ApoE
DKO mice were significantly decreased to about ,80% of plasma
IgM levels of ApoE
2/2 mice (p,0.001; Figure 3 E). Significant
reductions of plasma IgM prompted us to investigate whether IgM
deposits were also altered in atherosclerotic lesions of BAFF-R
2/2
ApoE
2/2 mice. Indeed, we found that IgM deposits in
atherosclerotic lesion were also decreased to 60% in BaffR.ApoE
DKO mice compared to ApoE
2/2 mice (p,0.01; Figure 3 D).
Decreased T cells and PCNA-positive cells in lesions of
BaffR.ApoE DKO mice
Next we asked if there were any reductions in T cells and
PCNA-positive cells in lesions of BaffR.ApoE DKO mice that
could account for the reductions in lesion size. CD4+ and CD
8+ T cells as well as PCNA+ cells are cellular markers of
inflammatory responses and active proliferative activity in
atherosclerosis [15–17]. Using CD4, CD8 and PCNA-specific
antibodies, we found that CD4+ T cells and proliferating PCNA+
cells were reduced by 69% (p,0.05) and 76% (p,0.05)
respectively in lesions of the BaffR.ApoE DKO mice compared
to ApoE KO mice. In addition CD8+ T cell numbers were
reduced by 49% (p,0.05; Figure 4).
Reductions in VCAM-1 expression and dendritic cells in
lesions of BAFF-R
2/2 ApoE
2/2 mice
We carried out immunohistochemical assays to determine
whether expression of VCAM-1 in atherosclerotic lesions was
affected by BAFF-R gene disruption. VCAM-1 regulates the
migration of leukocytes, including monocyte infiltration into
developing lesions [18] and promotes the differentiation of
monocytes into macrophages and dendritic cells to sites of
inflammation [19]. Data analysis indicated that expression of
lesional VCAM-1 in BAFF-R-deficient mice showed a ,79%
decrease compared to BAFF-R-competent mice (p,0.001;
Figure 5 A). We also found that CD11c+ immature dendritic
cells and CD83+ mature dendritic cells were reduced by 54%
(p,0.05) and 68% (p,0.001) in BaffR.ApoE DKO mice compared
to ApoE KO mice (Figure 5 B and C).
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PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29371Figure 1. BAFF-R deficiency attenuates selectively conventional B2 cells, not peritoneal B1a cells. (A) PCR analysis of BAFF-R gene
disruption was performed using DNA extracted from tails of BAFF-R
2/2 ApoE
2/2, BAFF-R
+/+ ApoE
2/2 and BAFF-R
+/+ ApoE
+/+ mice. (B) BaffR.ApoE
DKO mice showed that CD22
+ B cells were lowered in peripheral blood, peritoneal cavity, spleen and peripheral lymph nodes. (C) FACS analysis on
peritoneal cavity revealed that depleted B cells were conventional CD22+ CD5- B2 cells, not CD22+ CD5+ B1a cells comparing to ApoE KO mice. (D)A
representative FACS analysis of peritoneal cavity showed that only conventional CD22+ CD5- B2 cell population (left upper quadrant) was decreased
in BaffR.ApoE DKO and peritoneal CD22+ CD5+ B1a cell (right upper quadrant) was unaffected. Open bar=ApoE KO; Black bar=BaffR.ApoE DKO;
n=9–11 mice; **: p,0.01, ***: p,0.001.
doi:10.1371/journal.pone.0029371.g001
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in lesions of BaffR.ApoE DKO mice
IFN-c expression by CD4+ T cells is reduced by anti-CD20 B
cell depletion in atherosclerotic mice [6]. To determine whether
IFN-c and other proinflammatory cytokines and chemokines were
also reduced in BAFF-receptor deficient mice, we performed real-
time PCR analysis using mRNA extracted from aorta containing
atherosclerotic aortic arches. We found that expression of mRNA
encoding the proinflammatory cytokines TNF-a and IL1-b as well
as monocyte attractant MCP-1 were decreased to 57%, 77% and
51% respectively in BaffR.ApoE DKO mice (All p,0.05; Figure 6).
The expression level of IFN-c was reduced by 24%, but it was not
statistically significant (Figure 6).
Discussion
In this study, we have provided evidence that the attenuation of
atherosclerosis and decreased inflammatory responses in athero-
sclerotic lesions in BaffR.ApoE DKO mice is linked to a reduced B2
cell population. In accordance with our previous reports [5,7], the
development of atherosclerosis is potently ameliorated in an
environment where atherogenic B2 cells but not atheroprotective
B1a cells are reduced, as occurs in BAFF-R-deficient ApoE
2/2
mice.
The vast majority of conventional B2 B cells express BAFF-R
which is essential for BAFF mediated maturation as well as their
survival. Our data demonstrate that B2 cells are major regulators
of atherosclerosis development. These findings are consistent with
our previous observation that the adoptive transfer of B2 but not
B1a cells to either lymphocyte deficient or B cell deficient mice
aggravates atherosclerosis [5]. We suggest that targeting B2 cells
via the BAFF receptor that spares B1a cells may be more
therapeutically efficacious than B cell depletion strategies using
monoclonal antibody to CD20 that depletes both B2 as well as B1a
cells [5,6].
BAFF-R gene defect is associated with a strong, but not
complete, reduction of mature B cells, sparing the B1a cell in both
spontaneous mutation and knockout mice [13,14]. B cells
contribute to the production of immunoglobulins, particularly
subclass IgG type. IgG constitutes about 75% of immunoglobulins
in the circulation and is the major Ig class generated in adaptive
immune responses. Our finding of reduced circulating immuno-
globulin IgG1 and IgG2a in mature B cell-depleted BaffR.ApoE
DKO mice is consistent with the inability of immature transitional
B cells to efficiently differentiate into mature B cells [13,14].
IgG deposits are reported in both human and animal
atherosclerotic lesions [20–22]. The origin of IgG is yet to be
determined. It could arise from B cells and plasma cells in the
intimal or adventitial layer and/or the circulating IgG pool
[21,22]. In our study, both IgG1 and IgG2a detected in both
intimal and medial layers in BAFF-R-competent ApoE
2/2 mice
were almost undetectable in BAFF-R-deficient ApoE
2/2 mice,
despite reduced but still easily detectable, levels of these IgGs in the
circulation. Concurrently CD22+ B cells in atherosclerotic lesions
were reduced to almost none in BAFF-R deficient ApoE
2/2
mice. Taken together, it is likely that lesion IgG deposits found in
BAFF-R-competent ApoE
2/2 mice are mostly derived from B cell
and/or plasma cells located in the intimal or adventitial layers.
Plasma IgM levels at the end of the 8 week-HFD were also
decreased in BaffR.ApoE DKO mice consistent with a previous
report [14] and with the suggestion that BAFF-R also has a role in
germinal centre responses and in Ig class-switch DNA recombi-
nation [14,23,24]. The reduction in IgM deposits that we observed
in atherosclerotic lesions may be a consequence of the reduced
levels of circulating IgM. The residual levels of IgM deposits in
atherosclerotic lesions may represent natural IgM produced by
peritoneal Bla cells as we have previously reported [7].
Accelerated local inflammation responsible for progression of
atherosclerosis and its complications is mediated by atherogenic
cells as well as proinflammatory proteins in atherosclerotic lesions
[25]. Immune cells such as monocytes, macrophages, dendritic
cells and lymphocytes migrate into atherosclerotic lesions, to
contribute to inflammation by interacting with other proinflam-
matory immune cells [16–19]. Activated immune cells secrete a
range of pro-inflammatory cytokines to intensify the inflammatory
process locally. These cytokines promote both their own
production and the production of other cytokines and can also
target the cells that produce them as well as neighboring cells to
promote inflammation [26]. Thus, proinflammatory cytokines
produced by macrophages, dendritic cells, CD4+ and CD8+ T
cells promote the development and progression of atherosclerosis
as positive regulators.
VCAM-1 is an adhesion molecule required for recruitment of
lymphocytes and monocytes from the circulation into atheroscle-
rotic lesions [18,27–31]. Monocytes recruited into atherosclerotic
lesions further differentiate into macrophages and dendritic cells
[32]. Our results suggest that the recruitment and retention of
proinflammatory macrophages, dendritic cells and CD4 and CD8
T cells in atherosclerotic lesions are decreased due to low
expression of VCAM-1 in BaffR.ApoE DKO mice.
Macrophages are major proinflammatory cells in the patho-
genesis of atherosclerosis. They appear early in the atherosclerotic
lesion to drive the inflammatory process in atherosclerotic lesions.
We suggest that the reduced accumulation of macrophages
contributes to the attenuated inflammatory responses that result
in decreased atherosclerosis. It is also likely that the decreased
accumulation of T cells, contributes to the reduced arterial
Table 1. Non-B lymphocyte populations in spleen (610
6).
Non-B cells ApoE KO BaffR.ApoE DKO
Spleen CD4+ T cells 17.1362.86 18.9763.15
CD8+ T cells 13.9162.33 19.4263.29
NK cells 1.4460.09 1.0260.11
NKT cells 1.0060.04 0.860.13
Regulatory T cells 2.6760.42 2.3160.04
At the end of 8 week HFD, spleen cells are analyzed for non-B lymphocyte
populations (n=9–11 mice).
doi:10.1371/journal.pone.0029371.t001
Table 2. Factors contributing in atherosclerosis
pathogenesis.
ApoE KO BaffR.ApoE DKO
Bodyweight 30.9260.59 28.9761.06
Total cholesterol 19.8562.03 18.5661.74
HDL cholesterol 3.5460.33 2.9560.27
VLDL/LDL cholesterol 15.3561.77 13.4261.25
Triglycerides 2.6760.58 4.2161.00
At the end of 8 week HFD, body weight and plasma lipids were analyzed (see
text) (n=9–11 mice).
doi:10.1371/journal.pone.0029371.t002
Decreased Atherosclerosis in BaffR.ApoE DKO Mice
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recruitment, differentiation and activation of macrophages in the
early stage of inflammatory responses, but also in maintenance of
subsequent inflammatory responses [33]. The reduction of CD4 T
cells in atherosclerotic lesions may be attributed at least in part to
BAFF-R providing co-stimulatory signals [34] that augment Th1
inflammatory responses [35]. CD4+ T cells can activate
macrophages to produce pro-inflammatory cytokines such as
TNF-a, IL1-b, MCP-1 [36].
Our findings also clearly show that selective deficiency of B2 but
not B1a cells is accompanied by reduction in the lesions of, the
proinflammatory cytokines TNF-a, IL1-b and MCP-1 [16–18,25–
31,33,36]. We have also previously reported reduced TNF-a in
atherosclerotic lesions that accompany the reduced atherosclerosis
following B cell depletion by anti-CD20 monoclonal antibody
treatment [5]. The reduction in TNF-a appears to be the
consequence of depletion of B2 cells as these cells are known to
be significant producers of TNF-a [34,37]. Expression of IFN-c
showed a trend in reduction in BaffR-ApoE DKO mice, but the
result was not statistically significant. As TNF-a has been reported
to upregulate VCAM-1 expression [38], the reduced VCAM-1
expression is likely the result of reduced TNF-a expression. In
turn, the reduced VCAM-1 and MCP-1 expression in lesions may
likely contribute, at least in part, to the reduced numbers of pro-
inflammatory macrophages, dendritic cells, CD4 T cells and CD8
T cells in the lesions directly and to the reduced proinflammatory
cytokines produced by these cells indirectly. Given that B2 cells
have been ascribed antigen-presenting functions, it is likely that the
depletion in B2 cells directly contributes to the reduced entry of
CD4 and CD8 T cells into the lesions.
In addition to pro-inflammatory cytokines, actively proliferating
cells are an indicator for progression of advanced atherosclerosis.
In early and progressing atherosclerotic plaques, intimal macro-
phages are principal proliferative cells constituting about 50% of
cell proliferation as assessed by the proliferative cell nuclear
antigen antibody [15] whilst three dominant PCNA+ cell types
found in advanced plaques are macrophages, vascular endothelial
cells and smooth muscle cells. The reduced PCNA+ cells in intimal
atherosclerotic lesion in BaffR.ApoE DKO mice suggest less
proliferative activity in atherosclerotic lesions.
Control of inflammation comes to the forefront in the future
management of atherosclerosis. In a meta-analysis of studies on
the relationship between methotrexate and cardiovascular disease,
methotrexate was associated with a lower risk for CVD patients
with chronic inflammatory diseases, suggesting that direct
treatment of inflammation will reduce cardiovascular events
[39]. Currently the use of BAFF antagonists to target B cells to
modulate immune responses in autoimmune diseases is being
trialled and shows promising results in animal and human studies
[9,40–43].
Given that we have provided compelling evidence that BAFF-R
deficiency is associated with potent reduction in inflammation in
atherosclerotic lesions, we suggest that targeting the BAFF-R has
potential for therapeutic application in the management of
patients with atherosclerotic vascular disease.
Materials and Methods
Animals
C57Bl/6 mice deficient in both BAFF-R and ApoE genes were
generated from crossing BAFF-R
2/2 mice (from Klaus Rajewsky
of the Harvard Medical School) and ApoE
2/2 mice (from the
Jackson Laboratory). Experimental mice (6–8 week- old male
mice) were fed a high fat diet containing 21% fat and 0.15%
cholesterol (Specialty Feeds, Western Australia) for eight weeks.
Ethics statement
All animal experiments approved by the Alfred Medical
Research and Education Precinct (AMREP) animal ethic
committee (E/0708/2008/B) were carried out at the Precinct
Animal Centre, AMREP.
Figure 2. Deficiency of BAFF-R attenuates atherosclerosis. After feeding a HFD for eight weeks, BaffR.ApoE DKO showed decreased
atherosclerosis at aortic sinus as assessed by (A) oil-red O stained lipid accumulation and (B) CD68+ macrophage accumulation compared to ApoE
KO. Open bar=ApoE KO; Black bar=BaffR.ApoE DKO; n=9–11 mice; scale bar=100 mm; *: p,0.05, **: p,0.01.
doi:10.1371/journal.pone.0029371.g002
Decreased Atherosclerosis in BaffR.ApoE DKO Mice
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Genomic DNAs were extracted from tail samples using DNeasy
blood and tissue kit (Qiagen, Germany). PCR application was
carried out with 50 ng of genomic DNA in a single reaction vessel
containing 20 mM Tris-HCl pH 8.4, 50 mM KCl, 1.5 mM
MgCl2, 0.2 mM dNTP, 0.2 uM of each primer and .2 unit of
Taq DNA polymerase (Invitrogen). PCR condition was as follow:
initial denaturation step of 5 minutes at 95uC, 35 cycles of
10 seconds at 95uC, 30 seconds at 60uC and 30 seconds at 72uC
and final amplification step of 5 minutes of 72uC. Primers used
were ApoE-Com 59-GCC TAG CCG AGG GAG AGC CG-39;
ApoE-WT 59- TGT GAC TTG GGA GCT CTG CAG C-39;
ApoE-KO 59- GCC GCC CCG ACT GCA TCT-39; BAFF-R-
Com 59-TTC TTT GAG CGG AGG CCA GG-39; BAFF-R-WT
Figure 3. BAFF-R deficiency responsible for loss of B2 cells affects loss of B cells and IgG deposits in atherosclerotic lesion and
attenuates plasma IgG levels. (A) CD22+ B cells and (B–D) immunoglobulins deposits (IgG1, IgG2a and IgM) found in the atherosclerotic lesion of
ApoE KO mice were not detected in BaffR.ApoE DKO mice. (E)The plasma IgG1, IgG2a and IgM levels are also significantly decreased in BaffR.ApoE
DKO but to a lesser extent than in lesions. Open bar=ApoE KO; Black bar=BaffR.ApoE DKO; n=9–11 mice; scale bar=100 mm; **: p,0.01,
***: p,0.001.
doi:10.1371/journal.pone.0029371.g003
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59-ATG GGC CAC TCA AGA TGA TCT G-39 (Genework,
Australia). PCR products were visualized on ethidium-stained
1.5% TAE agarose gel electrophoresis and digitally recorded.
Lymphocyte analysis
Lymphocytes were analyzed using flow cytometry as described
[5]. Flurochrome-labeled antibodies (all from BD Biosciences
unless otherwise stated) used were anti-CD22 (PE-Cat# 553384),
anti-CD5 (APC-Cat# 550035), anti-CD25 (APC-Cy7-Cat#
557658), anti-CD4 (Pacific Blue-Cat# MCD0428, Caltag Labo-
ratories), anti-CD8 (PerCP-Cat# 553036), anti-TCR-b (FITC-
Cat# 11-596185, eBioscience), anti-NK1.1 (PE-Cy7-Cat#
552878) and anti-foxp3 (PE-Cat# 12-5773-82, eBioscicence).
For surface markers, single cell suspension was stained with
multiple antibodies at 4uC for 30 minutes, washed away
unbounded antibodies and suspended in PBS with 1% FCS. For
regulatory T cells, anti-CD4 and anti-CD25 stained cells were
fixed, permeabilized and further stained with anti-foxp3 antibody.
FACS CantoII (BD Biosciences) was used to collect data from
different flurochrome-labeled cells. FACSDiva software (BD
Biosciences) was used to analyze the data.
Assessment of atherosclerosis
To assess the atherosclerosis, the aortic roots embedded in
OCT media were sectioned at 6 m thickness and stained with
Oil Red O (Sigma) to visualize lipid accumulation in aortic
intima as previously described by us [5]. Immunohistological
staining was also carried with anti-CD68 antibody (Cat#
MAC1957, Serotec) to assess macrophage accumulation in the
atherosclerotic lesions [5]. The lesion assessments were carried
out by quantifying the Oil Red O stained lipid accumulation
and CD68+ macrophage accumulation by Optimas software
[5].
Lesion cellular content analysis
Immunohistochemical staining was performed on aortic root
sections. Anti-mouse antibodies targeting CD4 (Cat# 550280, BD
Pharmigen), CD8 (Cat# 550281 BD Pharmigen), CD22 (Cat#
553382, BD Pharmigen), CD83 (Cat# 14-0831, eBioscience),
CD11c (Cat# 14-0114, eBioscience), VCAM-1 (Cat# 550547,
BD Pharmigen), PCNA (Cat# ab2426, Abcam), IgM (Cat#
550588, BD Pharmigen), IgG1 (Cat# 559626, BD Pharmigen)
and IgG2a (553391, BD Pharmigen) were used in primary
antibody incubation, followed by horse radish peroxidase-
conjugated secondary antibody for DAB substrate. All slides were
counter stained with H&E stain. Areas staining by CD11c,
VCAM, IgM, IgG1 and IgG2a antibodies were quantified by
Optimas software whilst cells stained with CD22, CD4 and CD8,
CD83 and PCNA were counted under light microscopy [5,44].
Both positive areas and positive cells were corrected to total lesion
areas as quantified by Optima software.
Figure 4. T cell infiltrates and cellular proliferative activity are decreased in atherosclerotic lesions of BaffR.ApoE DKO. (A and B)T
cell infiltrates as assessed by anti-CD4 and anti-CD8 antibodies and (C) cellular proliferative activity as assessed by PCNA antibody were reduced by
deficiency of BAFF-R. Open bar=ApoE KO; Black bar=BaffR.ApoE DKO; n=9–11 mice; scale bar=100 mm; *: p,0.05, **: p,0.01.
doi:10.1371/journal.pone.0029371.g004
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Determination of plasma cholesterol and triglycerides was done
using Beckman Coulter LX20PRO analyzer according to
manufacturer’s instructions.
Immunoglobulin analysis
Plasma immunoglobulin IgG1 and IgG2a were measured by
enzyme linked immnosorbent assay (ELISA). Nunc Maxisorp 96-
well ELISA plates were coated with 50 ml of 2 mg/ml goat anti-
mouse Ig antibody (Cat# 1010-01, Southern Biotech) overnight at
4uC. After addition of 50 ml of plasma diluted at 10
5, the plates
were incubated for 1 hour at room temperature. Secondary
antibody incubation was done for 1 hour at room temperature
with HRP-conjugated goat anti-mouse IgG1 (Cat# 1070-05,
Southern Biotech) and IgG2a (Cat# 1080-05, Southern Biotech)
antibodies for respective antibody measurement. TMB substrate
was used for color development. After stopping the reaction, optic
density was measured at 450 nm wave length using ELISA reader.
Plasma IgM was measured using rabbit polyclonal anti-mouse Ig
antibody (Cat Z0259, Dako) as coating antigen and HRP-
conjugated goat anti-mouse IgM (Cat GM-90P, ICL) as detection
antibody as previously described [7].
Real-time analysis of different mRNA
Aortas containing aortic arch and thoracic aorta were
immediately frozen in liquid nitrogen. According to manufactur-
er’s instructions, total RNA were extracted from aortas using
RNeasy fibrous tissue mini kit (Qiagen, Germany). RNA integrity
and quantity were determined using MultiNA electrophoresis
system (Shimadzu, Japan). One-step real-time PCR was carried
Figure 6. Real-time PCR analysis of proinflammatory cytokines.
RNAs extracted from aortic arches were analysed for proinflammatory
cytokines, TNF-a, IL1-b, MCP-1 and IFN-c. BaffR.ApoE DKO showed
reduced expression of proinflammatory cytokines in aortic arches
compared to ApoE KO. Open bar=ApoE KO; Black bar=BaffR.ApoE DKO;
n=9–11 mice; *: p,0.05.
doi:10.1371/journal.pone.0029371.g006
Figure 5. Low expression of adhesion molecule, VCAM-1, is associated with reduction in immature and mature dendritic cells in
atherosclerotic lesions of BAFF-R
2/2 ApoE
2/2 mice. (A) VCAM-1 expression decreased in atherosclerotic lesions by disruption of BAFF-R gene
was accompanied by (B) decreased immature dendritic cells as assessed by anti-CD11c antibody and (C) mature dendritic cells as assessed by anti-
CD83 antibody in BaffR.ApoE DKO mice. Open bar=ApoE KO; Black bar=BaffR.ApoE DKO; n=9–11 mice; scale bar=100 mm; *: p,0.05, ***: p,0.001.
doi:10.1371/journal.pone.0029371.g005
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Germany) on 7500 Fast Real-Time PCR system (Applied
Biosystem). The target gene expression levels were analyzed using
comparative cycle threshold method [45] with 18S rRNA primers
(Applied Biosystems). The primers used were as follows: IFN-c
sense (S) 59-AAG TTT GAG GTC AAC AAC CCA C-39, IFN-c
antisense (AS) 59-GCT GGC AGA ATT ATT CTT ATT GGG-
39; TNF-a (S) 59- TCT CAG CCT CTT CTC ATT CCT-39,
TNF-a (AS) 59- ACT TGG TGG TTT GCT ACG AC-39; MCP-
1 (S) 59-CTC AGC CAG ATG CAG TTA ACG-39, MCP-1 (AS)
59-GGG TCA ACT TCA CAT TCA AAG G-39; IL1-b (S) 59-
CCA CCT CAA TGG ACA GAA TCT CAA-39, IL1-b (S) 59-
GTC GTT GCT TGG TTC TCC TTG T-39.
Statistical analysis
SigmaPlot 10.0 was used for statistical analyses. Results are
presented as mean 6 SEM. Two-tailed unpaired student t tests
with Welch’s correction were used for statistical analyses. P values
were considered significant at P,0.05.
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